Ophthalmic medications pilocarpine

Gohen EM, Grim WM, Harwood RJ, Mehta GN. Solid state ophthalmic medication. United States Patent No. 4,179,497 1979. Harwood RJ, Schwartz JB. Drug release from compression molded films preliminary studies with pilocarpine. Drug Dev Ind Pharm 1982 8 663-682. 

The client with glaucoma is using an Ocusert system when applying pilocarpine, a miotic ophthalmic medication. Which intervention should the nurse discuss with the client ... 

Emulsions have been used for centuries for the oral administration of medical oils and vitamins and as dermatological vehicles. Recently, their application has been extended as drug carriers in the delivery and targeting of ophthalmic drags. An indomethacin emulsion has been reported to increase ocular bioavailability and efficacy compared to commercially available formulation in rabbits. 0.4% indomethacin emulsion showed 2.2 fold increase in the area under the anterior aqueous drag concentration/time curve compared to a 1% indomethacin suspension. The emulsion formulation also reduced ocular surface irritation caused by indomethacin Similar advantages have been shown for a pilocarpine emulsion which produced a prolonged therapeutic effect in comparison with pilocarpine hydrochloride eyedrops in man. It can be administered only twice a day, rather than four times daily for conventional formulation. 

The client diagnosed with open-angle glaucoma is prescribed pilocarpine (Isopto Carpine), miotic ophthalmic drops. The client is demonstrating instilling the medication. Which action by the client would warrant intervention ... 

The pilocarpine may cause blurred vision therefore, it should be applied at night. This is a special system that allows medication to be applied to the eye with an ophthalmic device. 

The client just diagnosed with glaucoma is prescribed pilocarpine, a miotic ophthalmic eye drop. Which statement indicates the client needs more teaching concerning the medication ... 

---